Buscar
Biontech SE
BNTXAñadir a la lista de seguimiento
93.575USD
+0.234+0.25%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
23.66BCap. mercado
PérdidaP/E TTM
Más Datos de Biontech SE Compañía
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Información de Biontech SE
Símbolo de cotizaciónBNTX
Nombre de la empresaBiontech SE
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Número de empleados6772
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 10
DirecciónAn der Goldgrube 12
CiudadMAINZ
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal55131
Teléfono4949613190840
Sitio Webhttps://www.biontech.com/
Símbolo de cotizaciónBNTX
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Ejecutivos de Biontech SE
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Desglose de ingresos
Divisa: USDActualizado: 12 de mar de 2025
Divisa: USDActualizado: 12 de mar de 2025
FY2019
FY2018
FY2017
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Estadísticas de accionistas
Actualizado: vie., 1 de may
Actualizado: vie., 1 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AT Impf GmbH
40.05%
Medine GmbH
15.87%
Fidelity Management & Research Company LLC
2.15%
T. Rowe Price Investment Management, Inc.
1.77%
PRIMECAP Management Company
1.50%
Otro
38.65%
Accionistas
Accionistas
Proporción
AT Impf GmbH
40.05%
Medine GmbH
15.87%
Fidelity Management & Research Company LLC
2.15%
T. Rowe Price Investment Management, Inc.
1.77%
PRIMECAP Management Company
1.50%
Otro
38.65%
Tipos de accionistas
Accionistas
Proporción
Corporation
56.27%
Investment Advisor
11.90%
Investment Advisor/Hedge Fund
3.82%
Research Firm
2.02%
Hedge Fund
1.53%
Individual Investor
1.15%
Sovereign Wealth Fund
0.73%
Pension Fund
0.20%
Bank and Trust
0.15%
Otro
22.23%
Participación institucional
Actualizado: dom., 5 de abr
Actualizado: dom., 5 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
802
51.86M
20.51%
-1.29M
2025Q4
771
54.72M
25.43%
-10.33K
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AT Impf GmbH
101.28M
38.45%
-572.68K
-0.56%
Dec 31, 2025
Medine GmbH
40.13M
15.24%
+5.09K
+0.01%
Dec 31, 2025
Fidelity Management & Research Company LLC
5.44M
2.07%
+465.54K
+9.35%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
4.48M
1.7%
-349.04K
-7.22%
Dec 31, 2025
PRIMECAP Management Company
3.80M
1.44%
-70.75K
-1.83%
Dec 31, 2025
Flossbach von Storch AG
4.20M
1.59%
-33.98K
-0.80%
Dec 31, 2025
Dodge & Cox
3.61M
1.37%
-32.60K
-0.89%
Dec 31, 2025
BNP Paribas Securities Corp. North America
1.58M
0.6%
+474.80K
+43.03%
Dec 31, 2025
Temasek Holdings Pte. Ltd.
1.51M
0.57%
--
--
Dec 31, 2025
Jane Street Capital, L.L.C.
1.36M
0.52%
+1.16M
+590.91%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
Ver más
Langar Global HealthTech ETF
Proporción4.06%
iShares Genomics Immunology and Healthcare ETF
Proporción3.6%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.42%
Global X Genomics & Biotechnology ETF
Proporción3.11%
WisdomTree BioRevolution Fund
Proporción2.74%
Franklin Genomic Advancements ETF
Proporción2.46%
VanEck Biotech ETF
Proporción2.38%
Virtus LifeSci Biotech Products ETF
Proporción1.58%
ProShares Ultra Nasdaq Biotechnology
Proporción1.02%
Invesco Nasdaq Biotechnology ETF
Proporción1.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
